News | April 13, 2026
Unichem’s US arm recalls Buspirone tablets after stability test OOS result
No adverse events reported; recall involves 5 mg 500-count bottles in the US market
No adverse events reported; recall involves 5 mg 500-count bottles in the US market
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract
This marks a meaningful step in the company's continued expansion in the region
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
The Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million
Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
